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Abstract
This study follows four large U.S. pharmaceutical manufacturers through periods prior, during,
and post major U.S. healthcare legislation. The focus of the study is to understand how top
management’s attention is affected by industry legislation. Using 18 years of letters to
shareholders from four U.S. pharmaceutical companies from 2001 to 2018, I analyzed the textual
data three ways using Provalis Research’s Wordstat software. First, I created word frequency
clouds to identify key words overall and for each period of time before and after legislation.
Second, using the “extraction” function in Wordstat, I used topic modeling to identify which
groups of words (or topics) emerged from the application of a standard topic modeling
algorithm. Finally, I applied pre-developed dictionaries of organizational constructs to the textual
documents to compare frequencies among these time periods. From these analyses, I identify
precautions and tactics used by executives of pharmaceutical manufacturers during periods of
healthcare reform.
Keywords: Pharmaceutical manufacturers, pharma, topic modeling, healthcare reform,
healthcare legislation, run-time, Affordable Care Act (ACA), Medicare Modernization Act
(MMA), Pfizer, Amgen, Johnson & Johnson, Bristol-Myer Squibb
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Major Healthcare Legislation: Effects and Reactions by Large U.S. Pharmaceutical
Manufacturers, 2001-2018
The United States operates a complex, multifaceted healthcare system, with players both
public and private, ultimately providing healthcare to the largest economy in the world.
Currently, the healthcare sector has come under great scrutiny based on affordability, level of
care, and coverage. Pharmaceutical manufacturers, specifically, play a large role surrounding the
current political affordability discourse as drug prices in the U.S. continue to rise. Although
pharmaceutical manufacturers are not the sole entity to blame for drug prices at the pharmacy
counter, they are the first in the pharmaceutical supply chain and set the beginning price of a
drug before markups by various other sub-industries.
As well, the U.S. has a large number of “middleman” entities in its system and inefficient
insurance companies. Having worked for a year trading and analyzing healthcare securities for
various healthcare sub-industries, I was able to identify a few “middleman” entities responsible
for high prices in the U.S. healthcare system.
Imagine if textbooks and school supplies went through “middlemen” before being
purchased by schools. Say a textbook company invests money and years of time creating a
textbook, but instead of being able to sell it directly to schools, they must sell indirectly to a
complex network of interconnected companies. For the example’s purpose, let’s imagine there
are textbook distributors, textbook stores, and textbook price insurance companies. Here,
roughly, is how all the companies would interact. Basically, textbook price insurance companies
would decide what books the schools could buy based on negotiated final textbook prices with
partner textbook distribution companies. In the meantime, textbook distribution companies
negotiate higher, marked-up prices to distribute textbooks to textbook stores based on the
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maximum price insurance companies said they would cover/pay. Simultaneously, the textbook
distributor is negotiating lower textbook prices with textbook manufacturers and searching for
cheaper, generic textbooks from different manufacturers. Finally, the textbook management
companies supply the textbooks stores with textbooks it knows insurance companies will cover
at approximately the price it knows the insurance company is willing to pay.
So, what is the point of this complex analogy? By the time a school goes to the textbook
store to buy the books its insurance company covers, the textbook has already been through two
middlemen who both marked up the price to the amount the insurance company is willing to pay.
The result, extremely high prices for textbooks based on negotiations between distributors,
sellers, and insurance companies. As time goes on, the insurance companies will have to
continually raise their premiums as the distributors and stores craftily estimate the insurance
coverage and compute a “sellable price.”
Surprisingly, this process is how drugs get to pharmacy counters. Instead of textbook
distribution companies and textbook sales companies, the entities are pharmacies and pharmacy
benefits managers who liaison between pharmaceutical manufacturers, pharmacies, hospitals,
and insurance companies to ultimately determine the final drug cost based on current legislation
and insurance coverage. Consequently, healthcare reform and legislation change these
interactions and influence manufacturers and the final drug price. Therefore, understanding the
interactions between manufacturers and healthcare legislation becomes imperative when
interpreting the pharmaceutical supply chain.
Without having complete power over the final drug price, pharmaceutical manufacturers
must tread carefully when navigating these complex negotiations. These manufacturers must
ensure the prices charged for the drugs, which they spend millions or billions on developing, are
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appealing to private insurance companies and Medicare/Medicaid. Note the pluralization of the
word prices above, pharmaceutical companies and their partner pharmacy benefits managers
often negotiate different prices for different insurance companies and Medicare/Medicaid.
Adding to pharmaceutical manufacturers’ stress, once a drug hits the market its patent
only lasts for a finite number of years before large generic manufacturers can launch an identical
drug at a fraction of the cost without having to incur massive research and development
investments. Additionally, not all developed drugs, which still cost millions to billions to
develop, gain FDA approval or are successful, so the costs of these failed drugs must be covered
by the profits of successful drugs, further inflating the price. When one considers all the factors
pharmaceutical manufacturers must take into consideration – what drugs to develop, the budget
for developing drugs, getting FDA approval, how much to sell drugs for, how much failed drug
investment needs to be recovered by the successful drugs, how long can they be sold, will
anyone buy or cover the drugs, and will legislation change effect any of the prior factors – the
strategy and process for manufacturing drugs becomes overwhelmingly complex.
Specifically, research and development costs are a differentiating factor between the
overall healthcare sector and pharmaceutical manufacturers. Compared to the rest of the sector,
the U.S. pharmaceutical industry spends nearly 15% more on research and development
annually, as shown on the next page by the “other” category in figure 1. The high proportion of
R&D costs reflects the highly competitive and complicated nature of the pharmaceutical market
and is evidence of manufacturers’ need to continually create new drugs.
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Figure 1: Despite seemingly harsh industry conditions, the pharmaceutical manufacturing industry in the
U.S. out-performs other areas of the healthcare sector. From: www.ibisworld.com

Ever since I began trading, studying, and analyzing the healthcare industry and healthcare
securities for the University of Tennessee, I became fascinated by how pharmaceutical
manufacturers survive. I have been especially intrigued by certain large manufacturers’ ability to
adapt to major healthcare reform. The focus of this research is to address this question: What are
those reactions – actions, attention and considerations – made by these companies across
legislative changes?
To address this research question and analyze manufacturers’ resiliency to legislative
change, I studied the reactions and behaviors of large pharmaceutical manufacturers during the
running time after a bill’s proposal/announcement and when the change has been enacted. To
gleam the best indication of a pharmaceutical manufacturing firm’s reaction and preparation for
legislative change, I will track what strategies the CEOs were pursuing or no longer pursuing
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during a bill’s runtime and post enactment phases. I will use three textual analysis approaches to
compare the focus of executive attention across three time periods. First, I will create word
frequency clouds to identify key words overall and for each period of time before and after
legislation. Second, I will use topic modeling to identify which groups of words (or topics)
emerged from the application of a standard topic modeling algorithm. Finally, I will apply predeveloped dictionaries of organizational constructs to the textual documents to compare
frequencies among these time periods. From these analyses, I identify precautions and tactics
used by executives of pharmaceutical manufacturers during periods of healthcare reform.
The Medicare Modernization Act (MMA) and the Affordable Care Act (ACA) constitute
the two largest and most recent legislative changes impacting the U.S. pharmaceutical
manufacturing industry. Therefore, my study is divided into three distinct phases: pre-MMA,
post-MMA/pre-ACA, and post ACA. These periods allow for analysis of executive attention
during the runtime and post legislative periods.
Author Background
My experience comes from years of undergraduate study surrounding the healthcare
sector. Early on, I served as a fund manager specializing in healthcare securities for the Haslam
College of Business where I researched, pitched, and traded pharmaceutical manufacturing
companies, insurance companies, and medical device firms. My most memorable experience
from my time on the fund was acquiring a newly vertically integrated firm in the pharmaceutical
supply chain world which had just completed a merger. The firm’s future looked bright, but I
miss predicted the effects of upcoming healthcare legislation, and, at the same time, the
Affordable Care Act was placed under question nationally by a Texas judge. The legislation and
the uncertainty surrounding the Affordable Care Act sent the sector through the floor, and my
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chosen firm’s bright future was flipped on its head. In short, the dramatic change fascinated me
and caused a newfound curiosity within myself towards these seemingly impossibly complicated
manufacturing firms.
In addition to my time as a fund manager, I took technical writing/editing for publication
classes where I frequently choose to study healthcare in my research. So, as my undergraduate
time is ending, I wanted to produce one final study on a largely misunderstood and confusing
sector to determine what really goes on within large pharmaceutical manufacturers.
Industry Background
Worldwide, healthcare varies drastically, but our own, in my opinion, holds first place
regarding complexity, number of players, and coverage issues. We are the largest economy in the
world and providing coverage on such a large scale undoubtably brings challenges and
complexity. However, many of these issues have become more prevalent as U.S. citizens struggle
to pay for their prescriptions, both with insurance and without.
This study will focus on the brand name pharmaceutical manufacturing industry in
relation to legislation change. Currently, brand name pharmaceutical manufacturing is a $188.4
billion industry 3,248 businesses strong. Exporting $44.2 billion worth of drugs in 2019 and
generating $35 billion in profits, the industry plays a large role in the overall healthcare sector
(Spitzer, 2019). According to the 2019 IBIS World Report, a few primary drivers for the brand
name pharmaceutical manufacturing industry are: federal funding to Medicare and Medicaid, the
median age of the U.S. population, the number of privately insured, and, of course, regulation
(Spitzer, 2019).
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Major U.S. Healthcare Legislation 101
To best understand U.S. pharmaceutical manufacturers’ ability to adapt to healthcare
change, one will benefit from knowledge of U.S. Healthcare history. Most know U.S. Healthcare
is a privatized system with public elements (Medicare and Medicaid), but how long has the
private/public approach really been around? According to Manchikanti, Helm, Benyamin, and
Hirsch (2017), the history of public United States Healthcare legislation began in 1965 when
President Lyndon B. Johnson passed Medicare and Medicaid into law. At last, President
Johnson’s historic act provided government coverage for the poor, needy, and elderly. Now,
pharmaceutical manufacturers had a new, very large client – the U.S. government.
Continuing through history, many revisions, additions, and subtractions were passed
modifying Medicare and Medicaid, and new government programs were added to supplement
the existing legislative structure. Now, pharmaceutical manufacturers, in conjunction with
insurance companies and pharmacy benefits managers, were battling to gain the business of both
the government and American citizens on private insurance. The next notable legislation change
comes in the 1990s with the Clinton administration. President Bill Clinton, with the help of first
lady Hillary, enacted the Health Security Act. The act created two new government
organizations: HIPPA – Health Insurance Portability and Accountability Act – and SCHIP – State
Children’s Health Insurance Program (Manchikanti et al. 2017). These programs protected
personal healthcare information and children’s healthcare rights. However, the two largest
sweeping overhauls to U.S. healthcare have come within the past 20 years.
Sweeping Change 1: Medicare Modernization Act, 2004-2006
The next legislative break came in the early 2000s. After the Clinton administration and
the democrats placed their stamp on healthcare in the 90s, the election of President George W.
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Bush gave Republicans an opportunity to shape healthcare reform. At the end of 2003, President
George W. Bush passed the Medicare Modernization Act (MMA). The act redefined and
modified existing parts of Medicare and Medicaid but, also, added new ones such as Medicare
Part D which governs drugs under the Medicare and Medicaid programs. To be clear, Medicare
and Medicaid only apply to those in the programs. Americans on private insurance are not
directly affected by Medicare and Medicaid.
To provide some scale, the MMA’s Part D policy was the most expensive addition to
Medicare in history at the time of its passage, and the legislation had a two-part goal: increase
senior citizen access to drugs and control escalating prescription drug prices. Medicare Part D
alone was estimated to cost between $450 to $750 billion during its first ten years (Balotsky,
2009). Before launching the industry into the new policy, an integration time was implemented
(or, as I will refer in this study, run/running time) during 2004 and 2005. The run time measures
came in the form of drug coupons for senior citizens to provide companies an easy transition
before the law came into full effect in 2006 (Balotsky, 2009). So, what exactly did
pharmaceutical manufacturers have to prepare and adapt for to take advantage of the new plan?
According to Megellas (2006), here are a few major MMA Part D parameters:
•

The Center for Medicaid Services set a tentative monthly premium of $37 ($448 per
year).

•

Participants have a $250 annual deductible.

•

“For drug costs between $251 and $2250, Medicare and the plan will share 75% of
the cost and the beneficiary will pay for the remaining 25%.”

•

“For drug costs between $2251 and $5100, the beneficiary is responsible for 100% of
the cost; this is referred to as the gap or doughnut hole.”
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“For drug costs exceeding $5100, Medicare will pay 80%, the plan will pay 15%, and
the beneficiary will pay 5%.”

Now consider yourself a CEO of a large Fortune 500 pharmaceutical manufacturer like
Amgen. Which price range would you target your drugs to fall under? Well, I suppose the better
question would be which price range would you not want your drugs to fall under? Obviously,
the doughnut hole range. While some believed the Medicare Modernization Act was a step in the
right direction, it does not take an expert to note it caused an ethical dilemma within the
pharmaceutical supply chain while firms navigated the new legislation.
However, while Part D was the major new supplement the MMA added, changes to other
parts of the bill dramatically affected firms in the pharmaceutical supply chain as well. For
example, Medicare Part B changes altered the way drugs were sold and acquired via a change in
government drug reimbursements (Megellas. 2006). The overall answer to the legislation seemed
instead to target the elderly and take advantage of the new pricing legislation.
The American Association of Retired Persons (AARP) monitored drug prices following
the implementation of the legislation and found the industry may be raising prices of prescription
drugs. Specifically, drugs used and needed by the elderly. During the first quarter of 2006, AARP
found 193 prescription drugs commonly used by Americans over 50 years old saw a price
increase of around 6.2% relative to their prices 12 months prior from pharmaceutical
manufacturers (Manchikanti et al. 2017). However, manufacturer prices for generic drugs saw
little price change. Additionally, the participating Part D insurance companies’ policies were
insufficiently negotiating against climbing prices. For example, the median price increase during
the same 12-month period for the twenty most popular senior citizen drugs was 3.7%
(Manchikanti et al. 2017). The Medicare Modernization Act (MMA) had substantial effects on

PHARMA MANUFACTURER’S REACTIONS TO HEALTHCARE LEGISLATION

13

the pharmaceutical supply chain, especially insurance companies and pharmaceutical
manufacturers, but the actual price containment left much to be desired.
So, what was the final result of the change on pharmaceutical manufacturers? By 2007,
one year after full enactment, manufacturers now had a 39 million strong Medicare Part D
market to sell drugs to (“Medicare Drug Plans Strong and Growing”). With Medicare Part D, the
government had inserted itself as a large client into the complex negotiations of the
pharmaceutical supply chain and caught the eye of many manufacturers hoping to sell new
drugs.
Sweeping Change 2: The Affordable Care Act, 2010
After a change in political parties occupying the White House, the 2008 presidential
election put democrats back in charge. Like today, voters a decade ago were concerned with the
U.S. Healthcare system, and the elected administration was ready to restart and refresh
government-based healthcare through the Affordable Care Act (ACA). Once implemented into
law, the ACA was regarded as the largest change to U.S. Medicare ever. According to
Manchikanti et al (2017), the Affordable Care act had three primary goals:
1. Increase the number of the insured.
2. Improve the quality of care.
3. Reduce the costs of healthcare.
The first and third being the most applicable to the U.S. pharmaceutical supply chain,
especially U.S. pharmaceutical manufacturers. The first increased the size of the government ran
healthcare market. The total increase to those insured under Medicare and Medicaid came
primarily through Medicaid expansion (Manchikanti et al. 2017). Medicaid enrollment increased
by approximately 13 million and Medicare increased by around 7 million, but, according to a
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2015 RAND Corporation study, nearly 6 million lost their coverage (Manchikanti et al. 2017).
No legislation is perfect and the ACA “widened the gap between providing patients the
mechanism of paying for healthcare and actually receiving it (Manchikanti et al. 2017).” More
specifically, the Affordable Act works well for certain protected classes but falls short for
working- and middle-class citizens as the level of aid from Medicaid is determined based on
one’s income level’s proximity to the federal poverty line (Manchikanti et al. 2017). Basically,
like the MMA’s doughnut hole for drug coverage, the ACA’s doughnut hole is the middle- and
working-class giving pharmaceutical manufacturers and other healthcare businesses a target
market and price range for certain classes of the insured.
Former President Bill Clinton summarizes the ACA: “so you have got this crazy system
where all of a sudden, 25 million more people have healthcare and then the people who are out
there busting it, sometimes 60 hours a week, wind up with their premiums doubled and their
coverage cut in half. It is the craziest thing in the world (Manchikanti).” Despite the confusion,
the ACA offers beneficiaries “10 – essential benefits” according to Manchikanti et al.’s (2017)
study:
1. Ambulatory patient services
2. Emergency services
3. Hospitalization
4. Maternity and newborn care
5. Mental health and substance abuse disorder services, including behavioral health
treatment
6. Prescription drugs
7. Rehabilitative and habilitative services and devices
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8. Laboratory services
9. Preventive and wellness services and chronic disease management
10. Pediatric services, including oral and vision care
Importantly, the ACA covered prescription drugs, and, unlike the MMA, most of the
ACA’s reach applied to Medicaid, not Medicare, meaning the age demographic under
government ran healthcare shifted down as Medicaid covers all ages and Medicare being
reserved for the elderly. So, from a pharmaceutical manufacturer’s perspective, they know the
government market now has twenty million more insured consumers that are younger and many
with prescription drug coverage. Surprising to some, expected to others, the ACA did not prevent
the rise of drug prices; in fact, the ACA escalated the increase in prescription drug pricing
(Manchikanti et al. 2017). So, what are pharmaceutical manufacturers doing during these periods
of change other than hiking prices? Is there a method to the madness? What strategies were
employed to keep pharmaceutical firms successful amidst strong competition and with high risk
businesses?
Methods
To study pharmaceutical companies and their focus during times of legislative change, I
chose to analyze four large U.S. pharmaceutical manufacturers by running advanced topic
modeling software over 18 years of letters to shareholders from each firm from 2001 to 2018. I
elected to analyze letters to shareholders because I wanted to see where CEO’s were shifting
their focus during periods prior, during (run time), and after large legislative change.
Content Analysis and Attention-Based View
Documented in Sonpar and Golden-Biddle’s 2007 academic paper, content analysis is
useful to identify how executive attention changes over time, according to an ABV or Attention-
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Based View of the firm. Generally, ABV’s goal is to provide information regarding how a firm
behaves and is based on the premise that an organization or firm’s behavior results from where it
places its focus or attention (Sonpar & Golden-Biddle, 2007). The flow works like so: a firm’s
top management’s attention to an issue trickles down influencing the organization’s attention to
the issue and ultimately results in the firm taking action towards the issue.
Content analysis and the ABV model were used in a 2006 study of Regional Health
Authorities (RHA) in the Canadian province of Alberta (Sonpar & Golden-Biddle, 2007). As
with my own study, many precautions were taken to ensure the accuracy and reliability of the
content analysis. The study archived all relevant published documents from the RHAs and the
government. Once archived, the documents were loaded into advanced software and special
topical dictionaries were compared to each document to identify a larger concept or topic. For
example, words like promotion, healthy, living, and protection were loaded into a dictionary
called wellness, so, when the software would see a high level of those words in a document, it
would mark the document as containing the topic of wellness indicating management’s attention
to wellness (Sonpar & Golden-Biddle, 2007). Thus, the content analysis using an ABV
framework establishes causal relationships between certain programmed dictionary words to
topics.
Distinct from the RHA study, I located business-specific dictionaries tailored for my
content analysis software instead of crafting my own (See Appendix 1). To ensure accurate
information, I edited and created an extensive exclusion dictionary, which kept the software from
returning topics like the word “the” (See Appendix 3).
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Brand Name Pharmaceutical Manufacturers Studied
For my analysis, I chose four of the largest brand name pharmaceutical manufacturers
based in the U.S: Pfizer, Amgen, Bristol-Myers Squibb, and Johnson & Johnson. To ensure
accurate results, I gathered annual reports from 2001 to 2018 capturing periods prior, during
runtime, and after both the Medicare Modernization Act and the Affordable Care Act.

Figure 2: Depicts major U.S. brand name pharmaceutical manufacturers by increasing market share left
to right.

Pfizer Inc.

According to the IBIS Industry report for brand name pharmaceutical manufacturers
(Figure 1), research-based Pfizer Inc. is the world’s largest pharmaceutical company and
conducts most of its business in the U.S. capturing 11.8% of the total U.S. pharmaceutical
industry’s market (Figure 2). Headquartered in New York with a global research facility network,
the pharmaceutical giant serves two distinct business segments: innovative health and essential
health (Spitzer, 2019). Lipitor, Norvasc, and Zoloft are a few recognizable drugs Pfizer currently
sells. However, Pfizer’s full portfolio of drugs includes vaccines, small molecule medicines, and
biologics (Spitzer, 2019). Overall, Pfizer has stood the test of time in the U.S. pharmaceutical
industry since its inception in 1849.
Amgen Inc.
The youngest brand name pharmaceutical business in this study, Amgen Inc. specializes
in developing biopharmaceutical products for human therapeutics (Spitzer, 2019). The 2019 IBIS
Industry report indicates an industry market share of 9.7% for Amgen. With a human
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therapeutics focus, Amgen focuses on therapies for oncology/hematology, cardiovascular
disease, bone health, inflammation, nephrology, and neuroscience (Spitzer, 2019). A few
recognizable drugs from Amgen include Neulasta, Enbrel, and Prolia. While Amgen sells
products worldwide, it relies heavily on pharmaceutical distributors for sales within the U.S.
accounting for 96% domestic sales in 2017 (Spitzer, 2019). Resultingly, Amgen, like the rest of
the studied firms, has a large exposure to U.S. healthcare legislation.
Bristol-Myers Squibb
Another manufacturer who has stood the test of time, Bristol-Myers Squibb is an
important U.S. name brand pharmaceutical manufacturer. However, unlike the Pfizer and
Amgen, Bristol-Myers Squibb’s once great market share – the second largest pharmaceutical
company in the world in 1989 – has since dwindled. Now, the firm only controls 6.9% of the
U.S. name brand pharmaceutical industry (Spitzer, 2019). Operating solely in
biopharmaceuticals, the firm’s focus is on cancer treatments. Like Pfizer, Bristol-Myers Squibb
is headquartered in New York and conducts the majority (56%) of its business domestically. A
few recognizable drugs from Bristol-Myers Squibb are Eliquis and Opdivo (Spitzer, 2019).
While Bristol-Myers Squibb may not be leading the industry, it still remains a key player in the
U.S. today.
Johnson & Johnson
Likely the most recognizable brand of the studied firms, Johnson & Johnson currently
holds the second largest market share of the U.S. pharmaceutical market. Slightly different from
the rest, Johnson & Johnson is a holding company with over 260 companies under its name.
However, the entire Johnson & Johnson enterprise can be broken down to three lines of business:
pharmaceutical, consumer products, and medical devices (Spitzer, 2019). Dissecting its
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pharmaceutical arm, the firm currently serves six therapeutic areas: immunology, vaccines,
nervous system disorders, oncology, metabolism and pulmonary hypertension, and
cardiovascular. A few recognizable drugs from the firm are Remicade, Topamax, and Procrit
(Spitzer, 2019). Johnson & Johnson, then, is the most diversified company included in the study,
and its pharmaceutical branch has managed to edge out dedicated pharmaceutical manufacturers.
Data Analysis
For my research, I focused on 71 letters to shareholders spanning from 2001 to 2018 from
four major U.S. pharmaceutical manufacturers (18 letters from each, with the exception of 17
letters from Bristol-Myers Squibb) to capture where top management’s attention was during a
given period as outlined in the ABV approach. I utilized my university’s extensive resources to
find content analysis software (Provalis Research’s QDA Miner and Word Stat programs). I
undertook three text analysis approaches: word frequencies, topic modeling, and dictionary
application.
After all the letters to shareholders and dictionaries were loaded into the program, I chose
to conduct a few different types of content analyses. For my first analysis, I divided the letters
into three periods and identified word frequencies for each time period. The word frequencies are
represented by word clouds from each period; these word clouds represent the most important
keywords from a given period ranked by frequency per 10,000 words. Second, I used the topic
modeling algorithm in Wordstat to identify the groups of words or topics for each period group.
Finally, I overlaid dictionaries previously created in management research (Appendix 1) onto the
letters from each period as another method to understand and statistically compare the attention
of top management over these legislative periods.
The breakdown of the periods studied is shown below:
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1. Pre-Medicare Modernization Act (2001 – 2003)
2. Post-Medicare Modernization Act/Pre-Affordable Care Act (2004 – 2009)
a. First MMA legislative changes went into effect in 2004 and were finalized
in 2006
3. Post-Affordable Care Act (2010 – 2018)

Findings & Discussion
What are the reactions – actions, attention and considerations – made by these companies
across legislative changes? The areas of focus across the studied periods did change; however,
the resulting changes from top management were more often alike to shifts in focus rather than
prominently introducing new focuses or dismissing old ones period to period. For example,
major words in the word frequency clouds (Figures 3,4,5, and 6 on the following pages) show
words from period to period gradually coming in and going out of focus, but few prominent
words in one section disappear all altogether or appear only once. These shifts in focus, then,
represent attention trade-offs from top management across legislative changes instead of entirely
new strategic focuses tailored to each change. So, what are these focus-shifts before, during, and
after legislative change, and what do they tell us about how these companies prepare and adapt to
changes?
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Analysis of the Entire Study Period, 2001-2018

Figure 3: Depicts word frequency over entire period studied from letters to shareholders.

The word frequency analysis in Figure 3 yielded findings for the overall period. Depicted
above, the overall word frequency cloud shows words which the four firms’ top management
wrote the most over the date range (2001 – 2018). Note, the larger, more centralized the word the
more frequent the word arose in the CEOs’ letters to shareholders. Health, care, products,
medicines, world, and people have been primary focuses of CEOs for the past twenty years,
which, in turn, tells us the primary focuses of the firms over the time period. Surprisingly,
strategy and the consumer gleamed relatively little focus from the firms over the period, but the
larger emphasis on people over consumers implies large pharmaceutical manufacturers see their
clients as people instead of consumers.
The topic model produced from the entire data range yielded interesting, surprising
results. The topics, ranked from greatest attention by management to lowest attention by
management follow as such (See Appendix 2 for full topic model results):
1. HIV/AIDS
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2. Clinical Trials Lung Cancer
3. Medical Devices
4. Ownership Culture
5. Therapeutic Areas: Discovery and Development
The topic model informs us that during the entire date range brand name pharmaceutical
manufacturers focused on producing new therapies/products. During the past twenty years, the
top two areas of pharmaceutical manufacturer focus were AIDS and lung cancer. These make
sense as areas of focus for manufacturers as they were, and still are, large areas of need within
the pharmaceutical community. However, they are not the focus of firms today; the model overall
shows the scale of the focus for AIDS and lung cancer as they held the most attention from large
pharmaceutical companies. Additionally, we see the other remedy for preparing for legislative
change during runtimes from the ownership culture topic. By focusing internally, the firms
strengthen themselves to be best prepared for an uncertain future.
Period 1: Pre-Medicare Modernization Act, 2001-2003

Figure 4: Depicts word frequency over years 2001-2003 from letters to shareholders.
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Period 1 or the Pre-Medicare Modernization Act time period provides a glimpse into
what the firms were doing before any major healthcare reform was enacted, only the run time
preparations for the upcoming Medicare Modernization Act are reflected above. Unlike the word
cloud for the entire period 2001-2018, the attention of CEOs during this period was more
business centered and internally focused. The words year, company, business, and products
occurred the most during the period; therefore, in anticipation of legislation, the firms seem to
prepare themselves by growing their product line and in turn strengthening business. Recall, the
Medicare Part D provision first rolled out with the Medicare Modernization Act, so the internal
focus makes since as the firms all wanted to be prepared to take on the new, vast governmentbacked Part D plan.
The topic model falls somewhat in line with the word frequency cloud for this period.
The topics produced by the content analysis from period one are as follows (See Appendix 2 for
full topic model results):
1. Worldwide Sales Operational Growth
2. Research and Development
3. Pharmaceutical Company and People
4. Healthcare
5. Key Leadership
6. Food and Drug Administration Patents
7. Financial Performance/Corporate Governance
The topics for the first period carry some of the same themes as the word frequency cloud
but show more specific areas of focus. For example, instead of year and company as the top two
focuses, the topic model went into more detail informing us the primary focus of management
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was worldwide sales operational growth. This shows us that the companies were attempting to
take out an insurance policy, so to speak, during the run time for the Medicare Modernization Act
by way of strengthening foreign drug sales unaffected by the legislation. Additionally, the topics
of corporate governance and key leadership strongly indicate a push for internal stability before
the legislative landscape for drugs changed.
The topics research and development and Food and Drug Administration patents show a
second avenue of precaution taken during the time period. Pharmaceutical manufacturers are
always focused on their drug pipeline and ensuring they have enough upcoming products to take
place of older ones, but the topics were more defined during this period than the overall analysis.
Therefore, I am inferring that the companies were ramping up their product lines to ensure sales
stability/growth during the changing period and to prepare products for the upcoming Medicare
Part D.
Overall, the brand name pharmaceutical manufacturers appeared to be cautiously
optimistic during the run time before the Medicare Modernization Act. First, they focused on
growing the areas of the business largely unaffected by the change – overseas sales. However,
their next priorities were to internally strengthen their leadership structure and grow their
pipeline, areas of focus which help the firms take advantage of both global and domestic sales. It
seems clear then, that the manufacturers were mitigating future risks during the run time before
legislation took effect. The manufacturers placed bets on their international abilities and
strengthening their own leadership and products to fully take advantage of the new legislative
change.
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Period 2: Post-Medicare Modernization Act/Pre-Affordable Care Act, 2004-2009

Figure 5: Depicts word frequency over years 2004-2009 from letters to shareholders.

The second period’s word frequency cloud shows subtle changes from the prior period
indicating some post-Medicare Modernization Act changes and evidence of preparations in
anticipation of the upcoming Affordable Care Act. Words like year, products, and business
shrank relative to the period one cloud, and words like growth, care, and health grew. The largest
difference is the change from an overall internal focus to a new overall external growth focus.
The topic model produced from the letters in period two reflects the main focus of the
word cloud: growth. Below are the topics, again ranked by most attention from management (See
Appendix 2 for full topic model results):
1. Stage Pipeline
2. Sales Growth
3. Unmet Medical Disease Areas
4. Medical Devices
5. Patients
6. Research and Development
7. Company Performance
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Undoubtably, the manufacturers focused on rapid growth after the enactment of the
Medicare Modernization Act. The growth focus in the period following the Medicare
Modernization Act indicates the firms successfully weathered the legislative change and nuances,
and they now were in full expansion and growth mode. Looking at the topics in context with the
rest from the period, there is no topic which is not centered around growth and external focuses.
Overall, it appears after the passage of the Medicare Modernization Act firms expanded as
rapidly as possible during the brief period of semi-legislative stability.
More interesting than the growth focus, the lack of strong internally focused themes and
attention areas from management is contradictory to the manufacturer’s actions in anticipation of
the Medicare Modernization Act in the first period. The difference represents a break in
procedure from the first sweeping legislative change to the second. I hypothesize the firms now
had recent experience with dealing with large change, and the internal strengthening measures
taken in preparation for the Medicare Modernization Act were deemed good enough by top
management to not call for more in anticipation for the Affordable Care Act. Interestingly, the
firms did not focus abroad in anticipation of the Affordable Care Act like they had done for the
Medicare Modernization Act.
Further, the Affordable Care Act, while it was a large change, did not introduce an
entirely new government drug coverage plan like the Medicare Modernization Act from a
pharmaceutical manufacturing perspective. Rather, it altered Part D and changed the way
businesses farther up the supply chain interacted with Part B. Importantly, the focus of the
Affordable Care Act was to give all Americans access to health insurance. For pharmaceutical
manufacturers, the change meant more Americans would have health insurance, so it was more
likely than not that more Americans would buy prescription drugs. With the potential for the
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Affordable Care Act to grow the number of covered Americans, the focus on growth makes sense
as it prepares the firms to keep up with the potentially larger market.
Overall, the run-time preparations of growth and expansion for the Affordable Care Act
are largely like the post-Medicare Modernization Act adaptations. However, the difference
between run time preparations for the two bills indicates a lack of faith by the pharmaceutical
manufacturers for the first sweeping change, but, for the second, the manufacturers had already
learned to deal with new government drug programs and were more confident in their abilities to
sell and manufacture drugs.
Period 3: Post Affordable Care Act, 2010-2018

Figure 6: Depicts word frequency over years 2010-2018 from letters to shareholders.

The post-Affordable Care Act period’s word frequency cloud yielded a new focus. With
the firms having prepared and adapted for the Medicare Modernization Act and focused on
growth in anticipation from the Affordable Care Act, the name brand pharmaceutical
manufacturers found themselves in a stable legislative environment with no new major changes
on the horizon. So, what did they do? From the word cloud, it appears top management directed
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the firm’s attention to a customer focus. However, the apparent new patient focus may not be the
result of a new adaptation or change in response to the Affordable Care Act; rather, the word
patients has appeared in every word cloud and has grown with each one. The slowness of the
patient focus transition, taken into context with the other periods, seems the result of the
distraction of top management by the legislative pieces created to protect Americans. A
frustrating phenomenon arises. When the government passes legislature to help patients gain
access to drugs, the brand name pharmaceutical manufacturers take their focus off the patients.
Albeit the manufacturers’ shift in focus is only temporary, so, once the runtime period for
legislation ends, the patient becomes the center of attention for both the legislation and the
manufacturers.
The topic model for the final period reveals topics mostly in line with the main words in
the cloud. Although, a few new topics were introduced revealing new traits of brand name
pharmaceutical manufacturers. Below are topics produced by the modeling software from the
final period (See Appendix 2 for full topic model results):
1. Metastatic Melanoma (lung cancer)
2. Unmet Medical
3. Emerging Markets/Consumer Healthcare
4. Respect from Society/Trust
5. United States
6. Biopharma Company Long-term Success
For the first time, brand name pharmaceutical manufacturers display a sense of self
awareness and a more pronounced focus on long-term success. The new topic of respect and trust
from society indicates top management focused attention towards external appearances and
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perception for the first time. I hypothesize the shift is a result of both the Affordable Care Act
and the Medicare Modernization Act failing to lower drug prices as expected and the following
negative perception of the pharmaceutical industry by the public. A testament to the complex
pharmaceutical supply chain’s ability to adapt to legislative change, the pharmaceutical
manufacturers, as with legislation, quickly shifted attention and adapted to attempt to regain the
public’s faith.
The United States, unmet medical areas, and emerging consumer markets topics represent
attention shifts taken by top management to restore public relations. By showing an attention
shift and experimenting in new ways to expand customer markets and focus on the U.S.’s unmet
needs, the manufacturers are now making tangible changes in line with management’s focus on
growth via avenues that also appease the public. Playing into the dialogue of societally respectful
growth, the topic of long-term success also shows the manufacturers now can more effectively
strategically plan their business models without the burden of upcoming legislative change.
Ultimately, without the presence of legislative change, top management focuses attention on
appealing to the consumer and healthy, long-term growth instead of adapting to survive in new
legislative landscapes.
Comparison Across the Three Periods Using Dictionaries
While the topic models and word frequency clouds gave good qualitative insights to the
adaptations and strategies employed by pharmaceutical manufacturers, specialty business
dictionaries for content analysis provide another way to identify broad changes undertaken by
management across the three time periods. The dictionary analysis provides a word list for
particular constructs. These word lists are then overlaid on the textual materials to provide
frequency counts of words which can be used to statistically compare word frequencies across
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the three time periods. Instead of the computer program creating its own topics based on an
algorithm of words in the letters, using dictionaries can show how topics changed from period to
period and were statistically significant. The dictionary analysis is provided below in Figure 7.
1

Frequency/Word
Count

2

Frequency/Word
Count

3

Frequency/Word
Count

Chi2

INNOVATIVENESS

72

0.318%

259

0.428%

455

0.561%

25.735

0.000

PROACTIVE

75

0.332%

159

0.263%

205

0.253%

4.308

0.116

RISKTAKING

9

0.040%

41

0.068%

89

0.110%

13.082

0.001

ORIENTATION COMPETITOR

79

0.349%

282

0.466%

340

0.419%

5.855

0.054

Dictionaries

P (2-tails)

ORIENTATION CUSTOMER

44

0.195%

166

0.274%

188

0.232%

5.409

0.067

ORIENTATION INTERFIRM

107

0.473%

211

0.348%

412

0.508%

19.061

0.000

ORIENTATION LONG TERM FOCUS 157

0.694%

500

0.826%

754

0.929%

11.744

0.003

ORIENTATION PROFITS

103

0.455%

333

0.550%

384

0.473%

5.750

0.056

VIRTUE CONCIENTIOUSNESS

51

0.225%

149

0.246%

209

0.258%

0.675

0.714

VIRTUE INTEGRITY

15

0.066%

42

0.069%

54

0.067%

0.073

0.964

Figure 7: Dictionary frequency counts divided by total word count per page and resulting statistics
noting statistical change over periods.

The dictionary context analysis yielded interesting results both confirming and
questioning some of the results from the topic models. Some of the dictionaries found no
statistically significant change period to period, such as the organizational constructs of
proactiveness, conscientiousness, and integrity, while others displayed significant change. The
dictionary results mostly confirm the results of the topic models and word frequency clouds, and
this is explained below
Innovativeness showed the most significant change over the periods and reflects earlier
hypothesizes about the firms transitioning to new healthy ways of growth instead of rapid growth
to meet demands of new government programs. It also confirms the topics introduced in period
three which focus on emerging markets and new ways to regain trust. Note the slow transition
from period one to period three. The transition represents the tradeoff between government
legislation change and the pharmaceutical manufacturers’ focus on innovation as the periods
where change was introduced saw lower levels of innovation.
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Next, the interfirm statistic is another major confirmation of results from the topic models
and frequency clouds. The interfirm dictionary returned a higher level of interfirm focus during
the runtime for the Medicare Modernization Act followed by a drop after the legislation’s
enactment and during the run time for the Affordable Care Act. The period one to two change
represents the firms’ changing strategies for adapting to the Affordable Care Act and taking
advantage of the Medicare Modernization Act. Lastly, the return of the interfirm focus in the
third period likely represents the firms’ focus on regaining trust and establishing respect from
society.
Long-term focus and risk taking both saw statistically significant change over the
periods, each with an increased focus every period. The dictionaries’ findings surrounding the
two areas of focus agree largely with the discussion based off the topic models and frequency
clouds. Risk taking changed period over period in line with the initially conservative approach to
the Medicare Modernization Act, the rapid growth after, and the focus on emerging markets and
unmet medical needs. The long-term focus, like in the topic models, appears to be most apparent
in the latter periods.
Lastly, the customer focus dictionary, while just missing statistical significance, does
reflect a change over the periods. Conversely, the dictionary analysis seems to disagree with the
last period having the strongest focus on the customer, favoring period two. However, I take the
dictionary results hesitantly because the CEOs of major healthcare firms often do not use the
word “customer” and instead use “patient” or “people.” Unfortunately, the words patient and
people are not included in this dictionary. As a result, the unique vocabulary used by the brand
name pharmaceutical manufacturers when referring to customers likely skewed the dictionary
results, so the customer dictionary will be ignored for purposes of this study.
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Summary Table of the Three Analyses’ Findings:
Analysis
Type:
Word
Frequency
Cloud (Top
6 Words):
Topic
Model:

Entire Date
Range:

Period 1:
Pre-MMA

(2001-2018)

(2001-2003)

Health, Care,
Medicines,
Products,
People, and
World
N/A

Period 2:
Post-MMA/
Pre-ACA
(2004-2009)

Period 3:
Post-ACA

1. Worldwide Sales
Operational
Growth

1. Stage Pipeline

1. Metastatic
Melanoma (lung
cancer)

2. Research and
Development

3. Unmet Medical
Disease Areas

3. Pharmaceutical
Company and
People

4. Medical
Devices

Year, Company,
Business, Products,
World, and Sales

4. Healthcare
5. Key Leadership

Growth, Care,
Health, Company,
Medicines, and
Products

2. Sales Growth

5. Patients
6. Research and
Development

(2010-2018)

Patients, Year,
Company, Health,
Growth, and Medicines

2. Unmet Medical
3. Emerging
Markets/Consumer
Healthcare
4. Respect from
Society/Trust
5. United States

7. Company
Performance

6. Biopharma
Company Long-term
Success

Innovativeness:
= 0.318%
Risk taking:
= 0.040%
Interfirm:
= 0.473%
Long Term Focus:
= 0.694%

Innovativeness:
= 0.428%
Risk taking:
= 0.068%
Interfirm:
= 0.348%
Long Term Focus:
= 0.826%

Innovativeness:
= 0.561%
Risk taking:
= 0.110%
Interfirm:
= 0.508%
Long Term Focus:
= 0.929%

Firm’s focused
primarily internally
and on sales outside
U.S.

Firm’s focused
primarily on rapid
growth and new
markets.

Firm’s focused primarily
on patients and longterm success.

6. Food and Drug
Administration
Patents
7. Financial
Performance/Corporate
Governance

Dictionary:

Overall
Takeaways:

N/A
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Conclusion
U.S. pharmaceutical manufacturers operate in one of the most complex and everchanging industries in the world. With a lengthy supply chain passing through multiple
“middlemen” parties, large brand name pharmaceutical companies have managed to survive,
even prosper, during periods where their rules of operation change, and new legislation creates
different markets. These firms’ ability to adapt to legislative changes in stride is remarkable, and
they take great risks in doing so.
The two largest pieces of healthcare legislation in U.S. history happened over the last two
decades. The Medicare Modernization Act completely restructured public healthcare’s
pharmaceutical drug policies and represented a large potential client for many pharmaceutical
companies. Then, just six years later, the entire U.S. healthcare system was overhauled by the
Affordable Care Act. So how do the pharmaceutical manufacturers stay ahead?
In periods after a piece of legislation is announced and before enactment, large name
brand pharmaceutical manufacturers quickly adapt. My study found few similarities between the
run time before the Medicare Modernization Act and the Affordable Care Act, indicating
manufacturers tailor adaptations specifically to each piece of legislation. For the Medicare
Modernization Act, pharmaceutical manufacturers contracted by focusing internally on
leadership and corporate governance. To ensure stability, they also focused on sales channels
outside the U.S. For the Affordable Care Act, they focused more externally with top
management’s attention set on rapid growth and expansion via expanding product lines and
exploring unmet needs.
Once the legislation changes ceased, the pharmaceutical manufacturers shifted to a more
stable, healthy growth focus. The firms began to focus more on long-term success and rebuilding
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their societal reputation. Resultantly, they focused on the U.S. market and continued to explore
areas of unmet need. Overall, the manufacturers’ attention centered around their patients during
times without legislative change and towards themselves during times of change.
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Appendix 1 – Source of Organizational Dictionaries
•

•

•

EO – Innovativeness, Risk-taking, and Proactive Dictionaries
o Developed by: Short, J. C., Broberg, J. C., Cogliser, C., & Brigham, K. H.
(2010). Construct validation using computer-aided text analysis (CATA):
an illustration using entrepreneurial orientation. Organizational Research
Methods, 13, 320–347.
Market Orientation – Orientation Interfirm, Long Term Focus, Competitor,
Profits, Customer
o Developed by: Zachary, M. A., McKenny, A. F., Short, J. C., & Payne, G.
T. (2011). Family business and market orientation: Construct validation
and comparative analysis. Family Business Review, 24(3), 233-251.
Organization Virtue Orientation – Conscientiousness, Integrity
o Developed by: Payne, G. T., Brigham, K. H., Broberg, J. C., Moss, T. W.,
& Short, J. C. (2011). Organizational virtue orientation and family firms.
Business Ethics Quarterly, 21, 257-285.
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Appendix 2 – Topic Model Results
From Entire Period Studied (2001-2018):
NO

4

TOPICS - Entire Study Period

KEYWORDS
NET; DILUTED; ADJUSTED; PERCENT; SALES; INCOME; TOTAL;
EARNINGS; GAAP; OPERATIONS; GREW; REVENUES; INCREASE;
REPORTED;

DILUTED EARNINGS PER SHARE; NET SALES; ADJUSTED
DILUTED EARNINGS PER SHARE EARNINGS; ADJUSTED EARNINGS PER SHARE; ADJUSTED
NET SALES
DILUTED EARNINGS PER SHARE; CONTINUING OPERATIONS; NET
INCOME; PERCENT INCREASE; PERCENT OPERATIONALLY;
ADJUSTED INCOME; NET EARNINGS; SALES GREW; WORLDWIDE
SALES; BILLION IN SALES; SALES GROWTH; TOTAL NET SALES;
ADJUSTED COST OF SALES; PRODUCT SALES; SALES INCREASED;
TOTAL SHAREHOLDER RETURN;
AIDS; HIV; AFRICA; INITIATIVE; CHILDREN; COMMUNITY;
MILLION; ACCESS; FOUNDATION;

2

HIV AIDS

5

CLINICAL TRIALS
LUNG CANCER

3

MEDICAL DEVICES

7

UNITED STATES

6

OWNERSHIP CULTURE

1

THERAPEUTIC AREAS
DISCOVERY AND DEVELOPMENT

HIV AIDS; SECURE THE FUTURE; LIVING WITH HIV; SAHARAN
AFRICA; ACCESS PROGRAMS; INTERNATIONAL TRACHOMA
INITIATIVE; MEDICINES FOR FREE; PEDIATRIC AIDS; PEOPLE
LIVING; BLINDING TRACHOMA; RETURNING VETERANS; CHINA
AND INDIA; MEDICAL CARE;
CLINICAL; PHASE; CANCER; STUDIES; MELANOMA; DATA;
TREATMENT; TRIALS; LUNG; STAGE; ONCOLOGY; TYPE; LATE;
DISEASE; STUDY;
CLINICAL TRIALS; LUNG CANCER; STAGE PIPELINE;
CARDIOVASCULAR DISEASE; CANCER PATIENTS; CLINICAL DATA;
CLINICAL TRIAL; METASTATIC MELANOMA; PHASE ILL; BREAST
CANCER; CLINICAL STUDIES; STAGE CLINICAL; CANCER
TREATMENT; DISEASE AREAS;
DEVICES; DIAGNOSTICS; MEDICAL; SEGMENT; CARE; SURGICAL;
CONSUMER; PHARMACEUTICALS; PRODUCTS; HEALTH;
BUSINESSES;
HEALTH CARE; MEDICAL DEVICES; MEDICAL DEVICES AND
DIAGNOSTICS; CONSUMER HEALTHCARE; CONSUMER HEALTH;
CARE PRODUCTS; HEALTH CARE BUSINESSES; CONSUMER
HEALTH CARE; UNMET MEDICAL; GLOBAL HEALTH CARE;
UNITED; STATES; EUROPE; JAPAN;
UNITED STATES;
INTEGRITY; CULTURE; TRUST; VALUES; LONG; CUSTOMERS;
TERM; PEOPLE; COLLEAGUES; RESPECT;
LONG TERM; OWNERSHIP CULTURE; MANAGING FOR THE LONG
TERM; MILLIONS OF PEOPLE; RESPECT FROM SOCIETY;
COMMITMENT TO INTEGRITY; STRONG VALUES;
SCIENTIFIC; MANUFACTURING; THERAPEUTIC; DISCOVERY;
MEDICINES; ANNOUNCED;
DISCOVERY AND DEVELOPMENT; THERAPEUTIC AREAS;
MEDICINES AND VACCINES;

COHERENCE

FREQ

CASES

% CASES

0.456

610

64

91.43%

0.450

289

52

74.29%

0.418

694

63

90.00%

0.416

881

64

91.43%

0.368

147

44

62.86%

0.337

442

64

91.43%

0.312

246

59

84.29%
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From Period 1 (2001-2003):
NO

TOPICS - Period 1

5

WORLDWIDE SALES
OPERATIONAL GROWTH

2

3

KEYWORDS
SALES; PERCENT; BILLION; GROWTH; STRONG; WORLDWIDE;
MILLION; PRODUCT;

NET SALES; OPERATIONAL GROWTH; WORLDWIDE SALES; SALES
GROWTH; AVAPRO AVALIDE; SALES AND EARNINGS; CANCER
TREATMENT;
DEVELOPMENT; RESEARCH; COMPANIES; PHARMACEUTICAL;
RESEARCH AND DEVELOPMENT PIPELINE;
PHARMACEUTICAL COMPANIES
RESEARCH AND DEVELOPMENT; PHARMACEUTICAL COMPANIES;
PEOPLE; WORLD; COMPANY; YEARS; MILLION; GLOBAL;
PHARMACEUTICAL COMPANY
PEOPLE
PHARMACEUTICAL COMPANY; VALUED COMPANY; HIV AIDS;
CARE; HEALTH; MEDICAL; PRODUCTS;

6

HEALTH CARE

7

KEY
LEADERSHIP

1

FOOD AND DRUG
ADMINISTRATION
PATIENTS

4

FINANCIAL PERFORMANCE
CORPORATE GOVERNANCE

HEALTH CARE; CARE PRODUCTS; MEDICAL CARE; MEDICAL
DEVICES; SKIN CARE; BROADLY BASED;
KEY; LEADERSHIP; LEADERS; FUTURE; BUSINESS; GLOBAL;
PATIENTS; IMPORTANT; DRUG; TREATMENT; MEDICINES;
FOOD AND DRUG ADMINISTRATION; UNITED STATES;
PERFORMANCE; FINANCIAL; YEAR; CORPORATE;
FINANCIAL PERFORMANCE; CONSECUTIVE YEAR; CORPORATE
GOVERNANCE;

COHERENCE

FREQ

CASES

% CASES

0.453

233

10

90.91%

0.401

140

11

100.00%

0.388

178

11

100.00%

0.385

136

10

90.91%

0.383

119

11

100.00%

0.373

116

11

100.00%

0.367

128

11

100.00%

From Period 2 (2004-2009):
NO

TOPIC - Period 2

KEYWORDS
STAGE; LATE; COMPOUNDS; DEVELOPMENT; APPROVAL;
PIPELINE; REVIEW; FDA; REGULATORY; CLINICAL; CANCER;
POTENTIAL; FULL;

COHERENCE

FREQ

CASES

% CASES

6

STAGE PIPELINE

0.492

315

24

100.00%

5

SALES GROWTH
BILLION

CLINICAL TRIALS; STAGE PIPELINE; FULL DEVELOPMENT;
REGULATORY APPROVAL; STAGE CLINICAL; STAGE
DEVELOPMENT; PHASE III; ANNUAL REVIEW; REGULATORY
AUTHORITIES; PHARMACEUTICAL PIPELINE; REGULATORY
REVIEW;
BILLION; SALES; PERCENT; TOTAL; EARNINGS; ADJUSTED;
REVENUE; LINE; GROWTH; YEAR; INCREASED; DELIVERED;

0.446

465

24

100.00%

3

UNMET MEDICAL
DISEASE AREAS

UNMET MEDICAL; DISEASE AREAS; THERAPEUTIC AREAS;
INNOVATIVE MEDICINES; AREAS OF SIGNIFICANT;
CARDIOVASCULAR DISEASE; SIGNIFICANT UNMET MEDICAL;
PATIENTS PREVAIL;
DEVICES; DIAGNOSTICS; MEDICAL; CONSUMER;
PHARMACEUTICALS; CARE; BUSINESSES; HEALTH;

0.433

259

22

91.67%

4

MEDICAL DEVICES

0.428

369

21

87.50%

7

PATIENTS

HEALTH CARE; MEDICAL DEVICES; MEDICAL DEVICES AND
DIAGNOSTICS; CONSUMER HEALTH; CONSUMER HEALTH CARE;
HEALTH CARE BUSINESSES; BROADLY BASED; HEALTH CARE
PRODUCTS;
PATIENTS; MEDICINE; MEDICINES; SAFETY; PATIENT; CLINICAL;
WORLD; APPROVED; INDUSTRY; PEOPLE; MILLION; WORK;

0.405

478

24

100.00%

2

RESEARCH AND DEVELOPMENT
MANUFACTURING

0.364

214

23

95.83%

1

COMPANY
PERFORMANCE

0.360

397

24

100.00%

SALES GROWTH; ADJUSTED EARNINGS PER SHARE; CONTINUING
OPERATIONS;
AREAS; UNMET; DISEASE; INNOVATIVE; MEDICAL; THERAPEUTIC;
DISEASES; SIGNIFICANT; BUILDING; STRATEGY;

MILLIONS OF PEOPLE; CLINICAL TRIALS; PEOPLE AROUND THE
WORLD; CLINICAL DATA; CLINICAL TRIAL;
MANUFACTURING; PRODUCTIVITY; GLOBAL; RESEARCH; COST;
RESOURCES; DEVELOPMENT; LARGE; MARKETS;
RESEARCH AND DEVELOPMENT; EMERGING MARKETS; GLOBAL
RESEARCH; COST BASE; BIOMEDICAL RESEARCH; COST SAVINGS;
COMPANY; PERFORMANCE; MISSION; COMMITMENT; FUTURE;
LONG; CUSTOMERS; PAST; MAKE; HEALTH; CHANGE; FINANCIAL;
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From Period 3 (2010-2018):
NO

TOPIC - Period 3

4

PERCENT INCREASE

5

METASTATIC MELANOMA

2

UNMET MEDICAL
MOLECULES

1

EMERGING MARKETS
CONSUMER HEALTHCARE

3

RESPECT FROM SOCIETY
TRUST

6

UNITED STATES

7

BIOPHARMA COMPANY
TERM SUCCESS

KEYWORDS
PERCENT; BILLION; ADJUSTED; DIVIDEND; SALES; INCREASE;
TOTAL; CASH; RETURN; GREW; APPROXIMATELY; SHARE;
INCREASED; OPERATIONAL; YEAR;
SHAREHOLDER RETURN; PERCENT INCREASE; BILLION IN SALES;
CASH FLOW; PERCENT OPERATIONALLY; TOTAL SHAREHOLDER
RETURN; DIGIT GROWTH; ADJUSTED DILUTED EARNINGS PER
SHARE; ADJUSTED EARNINGS PER SHARE; CONSECUTIVE YEAR;
SHARE REPURCHASES; SALES GREW; ADJUSTED COST OF SALES;
ADJUSTED INCOME; BILLION TO SHAREHOLDERS; INCREASED
OUR DIVIDEND; INFORMATIONAL AND ADMINISTRATIVE
EXPENSES; PREVIOUS YEAR;
MELANOMA; CLINICAL; LINE; DATA; STUDIES; LUNG; PHASE;
IMMUNO; COMBINATION; ONCOLOGY; TREATMENT; CANCER;
POSITIVE; THERAPY;
LUNG CANCER; METASTATIC MELANOMA; CANCER PATIENTS;
TUMOR TYPES; CLINICAL DATA; CLINICAL TRIAL; CLINICAL
TRIALS; IMMUNE SYSTEM; CLINICAL STUDIES; ONCOLOGY
PORTFOLIO;
UNMET; MOLECULES; MEDICAL; PIPELINE; DISEASE; STAGE;
AREAS; EARLY; THERAPEUTIC; ADVANCING; POTENTIAL;
CARDIOVASCULAR; PHASE; DEVELOPMENT; RESEARCH;
UNMET MEDICAL; STAGE PIPELINE; THERAPEUTIC AREAS;
RESEARCH AND DEVELOPMENT; CARDIOVASCULAR DISEASE;
SIGNIFICANT UNMET; AREAS OF HIGH UNMET MEDICAL;
SIGNIFICANT UNMET MEDICAL;
MARKETS; EMERGING; CONSUMER; PHARMACEUTICALS;
BUSINESSES; PRODUCTS; BRANDS; GROWTH; KEY; BUSINESS;
OPERATIONAL;
EMERGING MARKETS; CONSUMER HEALTHCARE; GROWTH IN
EMERGING MARKETS; PHARMACEUTICALS BUSINESS; CONSUMER
HEALTHCARE BUSINESS; INNOVATIVE PRODUCTS; CONSUMER
BUSINESS; ANIMAL HEALTH; KEY PRODUCTS; MARKETS AROUND
THE WORLD; STRONG GROWTH;
TRUST; RESPECT; INTEGRITY; SOCIETY; CULTURE; INITIATIVE;
LIVES; COLLEAGUES; PEOPLE;
OWNERSHIP CULTURE; RESPECT FROM SOCIETY; GREATER
RESPECT; GREATER RESPECT FROM SOCIETY;
UNITED; STATES; EUROPE; PREVENTION;
UNITED STATES;
TERM; LONG; BIOPHARMA; COMPANY; FUTURE;
BIOPHARMA COMPANY; LONG TERM; TERM GROWTH; TERM
SUCCESS;

COHERENCE

FREQ

CASES

% CASES

0.452

516

35

100.00%

0.429

353

31

88.57%

0.406

454

34

97.14%

0.397

412

35

100.00%

0.387

209

31

88.57%

0.384

73

22

62.86%

0.330

256

34

97.14%
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Appendix 3 – Exclusion Words (high frequency words)
A
ABLE
ABOUT
ABOVE
ACCORDING
ACCORDINGLY
ACROSS
ACTUALLY
AFTER
AFTERWARDS
AGAIN
AGAINST
AIN'T
ALL
ALLOW
ALLOWS
ALMOST
ALONE
ALONG
ALREADY
ALSO
ALTHOUGH
ALWAYS
AM
AMGEN
AMONG
AMONGST
AN
AND
ANNUAL_REPOR
T
ANOTHER
ANY
ANYBODY
ANYHOW
ANYONE
ANYTHING
ANYWAY
ANYWAYS
ANYWHERE
APART
APPEAR
APPRECIATE
APPROPRIATE
ARE
AREN'T
AROUND
AS
ASIDE
ASK
ASKING
ASSOCIATED
AT
AVAILABLE
AWAY
AWFULLY
B
BACK
BE
BECAME
BECAUSE
BECOME
BECOMES
BECOMING
BEEN
BEFORE
BEFOREHAND
BEHIND
BEING
BELIEVE
BELOW
BESIDE
BESIDES
BEST
BETTER
BETWEEN
BEYOND
BOARD
BOARD_OF_DIR
ECTORS
BOTH
BRIEF
BRISTOL
BUT
BY
C
CAME
CAN
CANNOT

CANT
CAN'T
CAUSE
CAUSES
CEO
CERTAIN
CERTAINLY
CHAIRMAN
CHAIRMAN_AN
D_CEO
CHAIRMAN_AN
D_CHIEF_EXECU
TIVE_OFFICER
CHAIRMAN_OF_
THE_BOARD
CHANGES
CHIEF_EXECUTI
VE_OFFICER
CLEARLY
C'MON
CO
COM
COME
COMES
COMMITTEE
CONCERNING
CONSEQUENTLY
CONSIDER
CONSIDERING
CONTAIN
CONTAINING
CONTAINS
CORRESPONDIN
G
COULD
COULDN'T
COURSE
C'S
CURRENTLY
D
DEFINITELY
DESCRIBED
DESPITE
DID
DIDN'T
DIFFERENT
DIRECTOR
DIRECTORS
DO
DOES
DOESN'T
DOING
DONE
DON'T
DOWN
DOWNWARDS
DUE
DURING
E
EACH
EARNINGS_PER_
SHARE
EDU
EG
EIGHT
EITHER
ELIQUIS
ELSE
ELSEWHERE
ENBREL
ENOUGH
ENTIRELY
ESPECIALLY
ET
ETC
EVEN
EVER
EVERY
EVERYBODY
EVERYONE
EVERYTHING
EVERYWHERE
EX
EXACTLY
EXAMPLE
EXCEPT
EXECUTIVE_VIC
E_PRESIDENT
F

FAR
FEW
FIFTH
FIND
FIRST
FIVE
FOLLOWED
FOLLOWING
FOLLOWS
FOR
FORMER
FORMERLY
FORTH
FOUND
FOUR
FROM
FURTHER
FURTHERMORE
G
GET
GETS
GETTING
GIVE
GIVEN
GIVES
GO
GOES
GOING
GONE
GOT
GOTTEN
GREETINGS
H
HAD
HADN'T
HAPPENS
HARDLY
HAS
HASN'T
HAVE
HAVEN'T
HAVING
HE
HELLO
HELP
HENCE
HER
HERE
HEREAFTER
HEREBY
HEREIN
HERE'S
HEREUPON
HERS
HERSELF
HE'S
HI
HIM
HIMSELF
HIS
HITHER
HOPEFULLY
HOW
HOWBEIT
HOWEVER
I
I'D
IE
IF
IGNORED
I'LL
I'M
IMMEDIATE
IN
INASMUCH
INC
INDEED
INDEPENDENT
INDEPENDENT_
DIRECTORS
INDICATE
INDICATED
INDICATES
INNER
INSOFAR
INSTEAD
INTO
INWARD
IS

ISN'T
IT
IT'D
IT'LL
ITS
IT'S
ITSELF
I'VE
J
JOHNSON
JUST
K
KEEP
KEEPS
KEPT
KNOW
KNOWN
KNOWS
L
LAST
LATELY
LATER
LATTER
LATTERLY
LEAD_INDEPEN
DENT_DIRECTO
R
LEAST
LESS
LEST
LET
LET'S
LIKE
LIKED
LIKELY
LITTLE
LOOK
LOOKING
LOOKS
LTD
M
MADE
MAINLY
MANY
MAY
MAYBE
ME
MEAN
MEANWHILE
MERELY
MIGHT
MINE
MORE
MOREOVER
MOST
MOSTLY
MUCH
MUST
MY
MYERS
MYSELF
N
NAME
NAMELY
ND
NEAR
NEARLY
NECESSARY
NEED
NEEDS
NEITHER
NEULASTA
NEVER
NEVERTHELESS
NEW
NEXT
NINE
NO
NOBODY
NON
NONE
NOONE
NOR
NORMALLY
NOT
NOTHING
NOVEL
NOW
NOWHERE

O
OBVIOUSLY
OF
OFF
OFTEN
OH
OK
OKAY
OLD
ON
ONCE
ONE
ONES
ONLY
ONTO
OPDIVO
OR
OTHER
OTHERS
OTHERWISE
OUGHT
OUR
OURS
OURSELVES
OUT
OUTSIDE
OVER
OVERALL
OWN
P
PARTICULAR
PARTICULARLY
PER
PERHAPS
PFIZER
PLACED
PLAVIX
PLEASE
PLUS
POSSIBLE
PRESUMABLY
PROBABLY
PROLIA
PROVIDES
PUT
Q
QUE
QUITE
QV
R
RATHER
RD
RE
REALLY
REASONABLY
REGARDING
REGARDLESS
REGARDS
RELATIVELY
REPATHA
RESPECTIVELY
RIGHT
S
SAID
SAME
SAW
SAY
SAYING
SAYS
SECOND
SECONDLY
SEE
SEEING
SEEM
SEEMED
SEEMING
SEEMS
SEEN
SELF
SELVES
SENSIBLE
SENT
SERIOUS
SERIOUSLY
SEVEN
SEVERAL
SHALL
SHE
SHOULD

SHOULDN'T
SINCE
SIX
SO
SOME
SOMEBODY
SOMEHOW
SOMEONE
SOMETHING
SOMETIME
SOMETIMES
SOMEWHAT
SOMEWHERE
SOON
SORRY
SPECIFIED
SPECIFY
SPECIFYING
SQUIBB
STILL
SUB
SUCH
SUP
SURE
T
TAKE
TAKEN
TELL
TENDS
TH
THAN
THANK
THANKS
THANX
THAT
THATS
THAT'S
THE
THEIR
THEIRS
THEM
THEMSELVES
THEN
THENCE
THERE
THEREAFTER
THEREBY
THEREFORE
THEREIN
THERES
THERE'S
THEREUPON
THESE
THEY
THEY'D
THEY'LL
THEY'RE
THEY'VE
THINK
THIRD
THIS
THOROUGH
THOROUGHLY
THOSE
THOUGH
THREE
THROUGH
THROUGHOUT
THRU
THUS
TO
TOGETHER
TOO
TOOK
TOWARD
TOWARDS
TRIED
TRIES
TRULY
TRY
TRYING
T'S
TWICE
TWO
U
UN
UNDER
UNFORTUNATEL
Y
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UNLESS
UNLIKELY
UNTIL
UNTO
UP
UPON
US
USE
USED
USEFUL
USES
USING
USUALLY
UUCP
V
VALUE
VARIOUS
VERY
VIA
VICE_PRESIDEN
T
VIZ
VS
W
WANT
WANTS
WAS
WASN'T
WAY
WE
WE'D
WELCOME
WELL
WE'LL
WENT
WERE
WE'RE
WEREN'T
WE'VE
WHAT
WHATEVER
WHAT'S
WHEN
WHENCE
WHENEVER
WHERE
WHEREAFTER
WHEREAS
WHEREBY
WHEREIN
WHERE'S
WHEREUPON
WHEREVER
WHETHER
WHICH
WHILE
WHITHER
WHO
WHOEVER
WHOLE
WHOM
WHO'S
WHOSE
WHY
WILL
WILLING
WISH
WITH
WITHIN
WITHOUT
WONDER
WON'T
WOULD
WOULDN'T
X
Y
YERVOY
YES
YET
YOU
YOU'D
YOU'LL
YOUR
YOU'RE
YOURS
YOURSELF
YOURSELVES
YOU'VE
Z
ZERO
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